Status:
UNKNOWN
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Adenocarcinoma of Esophagogastric Junction
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert II adenocarcinoma of esophagogastric junction
Detailed Description
Objective: To compare the safety and clinical efficacy between transhiatal/transabdominal and thoracoabdominal approach for Siewert Ⅱ adenocarcinoma of esophagogastric junction. Methods: A prospectiv...
Eligibility Criteria
Inclusion
- 18\~75 years old
- The tumor center located at the esophagogastric junction(EGJ) line from 1cm above to 2cm below(SiewertⅡ) .
- Histological diagnosis of adenocarcinoma
- 4\. American Society of Anesthesiologists(ASA) physical status class is less than or equal to 3
- Informed consent of patients
Exclusion
- Patients with distant metastasis (M1) or invasion of surrounding organs
- History of esophagectomy and gastrectomy (including endoscopic mucosal resection/endoscopic submucosal dissection for gastric cancer and esophageal cancer)
- History of other malignant tumors within 5 years
- The researcher believes that the patient is not suitable to participate in the clinical trial
- Patients who persist in withdrawing from clinical trials
Key Trial Info
Start Date :
December 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT04910789
Start Date
December 11 2019
End Date
December 31 2025
Last Update
June 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853